Navigation Links
Dr. M. Fatih Yanik joins Intellimedix
Date:6/12/2013

ATLANTA, June 12, 2013 /PRNewswire-iReach/ -- Dr. M. Fatih Yanik has recently joined the team at Intellimedix and will oversee the company's new technology development efforts. Dr. Yanik is an associate professor in the Electrical Engineering department of MIT and heads the school's High-Throughput Neurotechnology Group. In 2011, he was awarded the most prestigious NIH award, the NIH Director's Pioneer Award, and is the youngest recipient in the history of this award. Dr. Yanik is also the first person ever to receive all of the top NIH awards:  the NIH Director's New Innovator Award, the NIH EUREKA Award, the NIH Transformative Research Award, and the NIH Director's Pioneer Award.

"Fatih Yanik is a pioneer in the development of technologies for regenerative neurobiology and development of innovative drug discovery models and platforms. Additionally, Dr. Yanik and his research team have developed a novel and groundbreaking method of creating induced pluripotent stem cells (iPSCs) using RNA-based technology that holds great promise for personalized neurobiology. Fatih brings a treasure trove of talent to Intellimedix," says Dr. Jeffrey Skolnick, Chief Scientist at Intellimedix.

"Intellimedix has a very dedicated and world-class team who is truly passionate about finding cures for epilepsy and other neurological disorders. I am truly excited to join them in this endeavor as we set out to improve the quality of life for many people," says Dr. Yanik.

Dr. Yanik will play a major role in developing novel technologies and guiding the research at Intellimedix's Cambridge, MA based lab.

About IntelliMedix:

IntelliMedix was founded in early 2012 with the purpose of developing and applying novel technologies to accelerate the discovery of new therapies for neurological diseases and creating new approaches for personalized medicine. They employ cutting-edge technology that includes gene sequencing, in silico screening, optogenetics, synthetic biology, and high-throughput in vivo and in vitro models. The company's current focus is on developing new treatments for Dravet Syndrome and other types of intractable epilepsy. For more information, please visit http://www.intellimedix.com

Media Contact:

Joanna Morrison Intellimedix, 770.399.9930, jmorrison@intellimedix.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE IntelliMedix
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
2. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
3. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. David F. Harty Joins Systech International as Vice President
6. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
7. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
8. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
9. Anthony Creed Joins DDSTUDIO As GM, Experience Design
10. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
11. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):